Health Insurance Pharmaceutical Spending Surpasses 27 Trillion Won... 24% of Total Medical Costs Spent on Drugs
NHIS Announces 2024 Analysis of Reimbursed Pharmaceutical Expenditures
Spending Rises Due to Expanded Coverage and Increased Use of Chronic Disease Treatments
Due to the increase in chronic diseases driven by an aging population and the strengthening of health insurance coverage, annual spending on reimbursed pharmaceuticals in Korea has surpassed 27 trillion won. The proportion of pharmaceutical expenditures within total healthcare costs has also reached nearly 24%, ranking Korea among the highest within Organization for Economic Cooperation and Development (OECD) member countries.
According to the status of spending on reimbursed pharmaceuticals analyzed by the National Health Insurance Service on March 23, 2024, Korea's health insurance pharmaceutical expenses amounted to 27.6625 trillion won, a 5.6% increase compared to the previous year's 26.1966 trillion won.
In the same year, total medical expenses covered by health insurance rose to 116.2375 trillion won, up 4.9% from the previous year's 110.8029 trillion won. The proportion of pharmaceutical spending in total medical expenses reached 23.8%, up 0.2 percentage points from 23.6% in the previous year.
According to OECD Health Statistics released in August last year, in 2023, pharmaceutical expenditures accounted for 19.4% of Korea’s current health expenditures, which is 5.0 percentage points higher than the OECD average of 14.4%. This places Korea seventh after Greece (26.7%), Hungary (23.1%), Slovakia (21.9%), Latvia (21.4%), Mexico (21.0%), and Lithuania (20.8%), and ahead of major countries such as Japan (17.6%), Germany (13.7%), and the United Kingdom (9.7%).
The top five therapeutic classes by pharmaceutical expenditure in Korea accounted for 11.2 trillion won, representing 40.4% of the total pharmaceutical spending of 27.7 trillion won. By therapeutic class, anticancer agents (3.1 trillion won), antiarteriosclerotic agents (3.1 trillion won), and antihypertensive agents (2.1 trillion won) topped the list.
Additionally, the top five ingredient groups by spending amounted to 2.6 trillion won, which accounted for 9.4% of total pharmaceutical expenditures. By ingredient, ezetimibe + rosuvastatin (700 billion won), choline alfoscerate (560 billion won), and atorvastatin (550 billion won) were the leading items.
The government is pursuing reforms to the health insurance pharmaceutical pricing system to enhance patient access to treatment through appropriate compensation for innovative and essential medicines, and to support the development of the pharmaceutical and bio industries by providing rewards commensurate with innovation efforts. The Health Insurance Policy Review Committee at the Ministry of Health and Welfare plans to table for decision on March 26 a pricing system reform proposal that includes price reductions for domestically produced generic drugs.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
An official from the National Health Insurance Service stated, "We will work to specify implementation plans in line with government policy directions and actively support the execution of tasks for public and pharmaceutical industry development in order to ease patients’ pharmaceutical cost burdens and ensure the sustainability of health insurance finances."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.